logo

For the Inventor, By the Inventor

Salt Lake City, UT, United States of America

Myrexis, Inc.


USPTO Granted Patents = 12

% Expired Patents = 66.7



Forward Citations = 15

Loading Chart...
Loading Chart...

50 inventors (with patents filed for the assignee):

goldMedal Mark B Anderson (6 out of 11 patents)

silverMedal Yevgeniya Klimova (3 out of 6 patents)

bronzeMedal Sui Xiong Cai (3 out of 87 patents)

4.  Adam Willardsen (3 out of 3 patents)

5.  Ashok Bajji (2 out of 11 patents)

6.  Rachel M Slade (2 out of 7 patents)

7.  Robert J Halter (2 out of 6 patents)

8.  Warren S Weiner (2 out of 10 patents)

9.  Se-Ho Kim (2 out of 3 patents)

10.  Rajendra Tangallapally (2 out of 3 patents)

11.  Kazuyuki Suzuki (2 out of 2 patents)

12.  Nilantha Sudath Sirisoma (2 out of 7 patents)

13.  Kirill Ostanin (1 out of 8 patents)

14.  Hong Zhang (1 out of 30 patents)

15.  Eric O Freed (1 out of 3 patents)


12 patents:

1. 9505800 - Extended triterpene derivatives (2016-11-29),
2. 8476285 - Purine-core inhibitors of HSP90 and their use in treating cancer (2013-07-02),
3. 8318425 - Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein (2012-11-27),
4. 8309562 - Compounds and therapeutical use thereof (2012-11-13),
5. 8258145 - Method of treating brain cancer (2012-09-04),
6. 8217073 - Pyrrole derivatives as therapeutic compounds (2012-07-10),
7. 8017780 - Therapeutic compounds and uses thereof (2011-09-13),
8. 7989462 - 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof (2011-08-02),
9. 7943146 - Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface (2011-05-17),
10. 7842805 - Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof (2010-11-30),
11. 7816099 - Enzyme assay and use thereof (2010-10-19),
12. 7799768 - [object Object] (2010-09-21),
Company Overview
Myrexis, Inc. is a biotechnology company based in Salt Lake City, Utah, focused on the development of innovative therapeutics for the treatment of cancer and other serious diseases. The company specializes in the discovery and commercialization of novel drug candidates, leveraging advanced research methodologies to address unmet medical needs. Myrexis aims to enhance patient outcomes through its commitment to scientific excellence and the advancement of targeted therapies in the biopharmaceutical landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

12 Patents

#116 in Salt Lake City, UT

#300 in Utah

#25,578 in US

#48,209 in the World

Salt Lake City, UT (US)
Salt Lake City, UT, United States of America

Myrexis, Inc.

Forward Citations = 15

50 inventors:

goldMedal Mark B Anderson (6 out of 11 patents)

silverMedal Yevgeniya Klimova (3 out of 6 patents)

bronzeMedal Sui Xiong Cai (3 out of 87 patents)

4.  Adam Willardsen (3 out of 3 patents)

5.  Ashok Bajji (2 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Myrexis, Inc.. Retrieved from https://idiyas.com/company/myrexis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…